Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of SIPI6398 tablets in major depressive disorder
CTR20251117Phase 2Completed
- Sponsor
- Zhongze Therapeutics
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZZ6398 in major depressive disorder (MDD), sponsored by Zhongze Therapeutics. Started Apr 2025; status: completed.
02
Drugs
ZZ6398
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20251117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251117.